Patents show all

40Applications18Issued

Clinical Trials show all

5N/A

SEC Filings show all

D4

SEC Form D Funding Events

DateOfferedSoldType
2014-03-18$16,649,997$16,649,997Equity
2013-03-20$7,592,976$7,590,476Equity
2012-08-30$700,000$700,000Debt, Option to Acquire, Security to be Acquired
2012-05-14$500,000$500,000Debt, Option to Acquire, Security to be Acquired

Key Executives

  • D. Michael Ackermann, PhD
    Executive Officer, Director
  • Ali Behbahani
    Director
  • William Link
    Director
  • Brook Byers
    Director
  • Mark Blumenkranz
    Director
  • Mark S. Blumenkranz, MD
    Director
  • William J. Link, PhD
    Director
  • Steve Waite
    Director
  • James Loudin
    Executive Officer